On September 15, 2026, GenScript Corporation's long position in GENSCRIPT BIO was passively diluted after the company issued 77,126,000 new shares under a general mandate. The number of shares held remained unchanged at 800.00 million shares. This was not an on-market dealing but a consequence of the company's share issuance.
Prior to the dilution, GenScript Corporation's long position in GENSCRIPT BIO was 800.00 million shares, representing 36.31%; following the new share issuance, the holding remained at 800.00 million shares, with the long position ratio passively declining to 35.08%.
Source: Hong Kong Exchanges and Clearing Limited.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments